Postulated vasoactive neuropeptide autoimmunity in fatigue-related conditions: a brief review and hypothesis.
Staines, Donald R · Clinical & developmental immunology · 2006 · DOI
Quick Summary
This paper proposes that ME/CFS and similar conditions may develop when the immune system mistakenly attacks certain chemical messengers in the body called vasoactive neuropeptides (VNs). These VNs normally help control heart rate, breathing, temperature, memory, and mood. The authors suggest that after infections or other triggers, people's bodies may lose the ability to recognize these messengers as 'self,' leading to immune attacks that could cause the widespread symptoms seen in ME/CFS.
Why It Matters
This paper addresses a fundamental question about ME/CFS pathogenesis by proposing a specific immunological mechanism (autoimmunity against vasoactive neuropeptides) that could explain the constellation of neurological, autonomic, immune, and cognitive symptoms patients experience. If validated, this mechanism could guide development of diagnostic biomarkers and targeted treatments for ME/CFS.
Observed Findings
Vasoactive neuropeptides (PACAP, VIP, CGRP) are distributed throughout the central and peripheral nervous systems, gut, adrenal gland, blood cells, and other tissues.
These neuropeptides serve multiple roles as hormones, neurotransmitters, neuroregulators, immune modulators, and neurotrophic factors.
Vasoactive neuropeptides and their receptors possess immunogenic potential and could theoretically become targets of autoimmune attack.
Vasoactive neuropeptides have primarily anti-inflammatory activity and are critical for cardiorespiratory function, thermoregulation, memory, concentration, and emotional regulation.
Inferred Conclusions
Loss of immunological tolerance to vasoactive neuropeptides following infection or other environmental triggers could result in autoimmunity that produces the neurological, autonomic, immune, and cognitive dysfunction characteristic of ME/CFS and similar fatigue syndromes.
Molecular mimicry, heat shock proteins, and CpG fragments may be the immunological mechanisms driving breakdown of tolerance to these VNs.
Vasoactive neuropeptide dysregulation represents a biologically plausible common pathway for multiple fatigue-related conditions and warrants investigation as a therapeutic target.
Remaining Questions
Is autoimmunity against vasoactive neuropeptides or their receptors actually present in ME/CFS patients, and can specific antibodies or T-cell responses be detected and quantified?
What This Study Does Not Prove
This hypothesis paper presents no experimental data, patient cohorts, or direct evidence of anti-VN autoimmunity in ME/CFS patients—it is a theoretical framework only. It does not establish causation, demonstrate that VN autoimmunity actually occurs in affected individuals, or prove that VN dysregulation is the primary driver rather than a secondary consequence of other pathological processes. Subsequent empirical studies would be needed to test these postulates.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Which specific infectious agents or triggers would initiate loss of tolerance to VNs through molecular mimicry, and what are the cross-reactive epitopes?
Do patients with different fatigue-related syndromes (ME/CFS, GWS, SIDS) share a common VN autoimmune signature, or does the specific VN target vary by condition?
Could modulation of VN signaling or immunosuppression of anti-VN responses reverse or ameliorate symptoms in affected patients?